ID   PAK4_HUMAN              Reviewed;         591 AA.
AC   O96013; B4DGG6; Q8N4E1; Q8NCH5; Q8NDE3; Q9BU33; Q9ULS8;
DT   24-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   15-MAR-2017, entry version 182.
DE   RecName: Full=Serine/threonine-protein kinase PAK 4;
DE            EC=2.7.11.1;
DE   AltName: Full=p21-activated kinase 4;
DE            Short=PAK-4;
GN   Name=PAK4; Synonyms=KIAA1142;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Lymphoma;
RX   PubMed=9822598; DOI=10.1093/emboj/17.22.6527;
RA   Abo A., Qu J., Cammarano M.S., Dan C., Fritsch A., Baud V.,
RA   Belisle B., Minden A.;
RT   "PAK4, a novel effector for Cdc42Hs, is implicated in the
RT   reorganization of the actin cytoskeleton and in the formation of
RT   filopodia.";
RL   EMBO J. 17:6527-6540(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Neuroblastoma;
RA   Melnick M.B.;
RL   Submitted (MAY-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=10574461; DOI=10.1093/dnares/6.5.329;
RA   Hirosawa M., Nagase T., Ishikawa K., Kikuno R., Nomura N., Ohara O.;
RT   "Characterization of cDNA clones selected by the GeneMark analysis
RT   from size-fractionated cDNA libraries from human brain.";
RL   DNA Res. 6:329-336(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 264-591 (ISOFORM 1).
RC   TISSUE=Brain, and Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 4).
RC   TISSUE=Eye, Pancreas, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION IN PHOSPHORYLATION OF BAD.
RX   PubMed=11278822; DOI=10.1074/jbc.M011046200;
RA   Gnesutta N., Qu J., Minden A.;
RT   "The serine/threonine kinase PAK4 prevents caspase activation and
RT   protects cells from apoptosis.";
RL   J. Biol. Chem. 276:14414-14419(2001).
RN   [9]
RP   FUNCTION, AND MUTAGENESIS OF SER-445 AND SER-474.
RX   PubMed=11313478; DOI=10.1128/MCB.21.10.3523-3533.2001;
RA   Qu J., Cammarano M.S., Shi Q., Ha K.C., de Lanerolle P., Minden A.;
RT   "Activated PAK4 regulates cell adhesion and anchorage-independent
RT   growth.";
RL   Mol. Cell. Biol. 21:3523-3533(2001).
RN   [10]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12356872; DOI=10.1083/jcb.200207008;
RA   Zhang H., Li Z., Viklund E.K., Stromblad S.;
RT   "P21-activated kinase 4 interacts with integrin alpha v beta 5 and
RT   regulates alpha v beta 5-mediated cell migration.";
RL   J. Cell Biol. 158:1287-1297(2002).
RN   [11]
RP   FUNCTION.
RX   PubMed=14560027; DOI=10.1128/MCB.23.21.7838-7848.2003;
RA   Gnesutta N., Minden A.;
RT   "Death receptor-induced activation of initiator caspase 8 is
RT   antagonized by serine/threonine kinase PAK4.";
RL   Mol. Cell. Biol. 23:7838-7848(2003).
RN   [12]
RP   FUNCTION.
RX   PubMed=15660133; DOI=10.1038/sj.emboj.7600543;
RA   Soosairajah J., Maiti S., Wiggan O., Sarmiere P., Moussi N.,
RA   Sarcevic B., Sampath R., Bamburg J.R., Bernard O.;
RT   "Interplay between components of a novel LIM kinase-slingshot
RT   phosphatase complex regulates cofilin.";
RL   EMBO J. 24:473-486(2005).
RN   [13]
RP   INTERACTION WITH ARHGEF2.
RX   PubMed=15827085; DOI=10.1242/jcs.02313;
RA   Callow M.G., Zozulya S., Gishizky M.L., Jallal B., Smeal T.;
RT   "PAK4 mediates morphological changes through the regulation of GEF-
RT   H1.";
RL   J. Cell Sci. 118:1861-1872(2005).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-474, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-41; SER-104; SER-148;
RP   SER-167; SER-181; SER-258; SER-267; SER-291 AND SER-474, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-181 AND SER-474, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-41; SER-104; SER-148;
RP   SER-167; SER-181; THR-187; SER-195; SER-258; SER-291 AND SER-474, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-181 AND SER-474, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [19]
RP   FUNCTION IN PHOSPHORYLATION OF ITGB5.
RX   PubMed=20507994; DOI=10.1074/jbc.M110.123497;
RA   Li Z., Zhang H., Lundin L., Thullberg M., Liu Y., Wang Y.,
RA   Claesson-Welsh L., Stromblad S.;
RT   "p21-activated kinase 4 phosphorylation of integrin beta5 Ser-759 and
RT   Ser-762 regulates cell migration.";
RL   J. Biol. Chem. 285:23699-23710(2010).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF RAN.
RX   PubMed=20805321; DOI=10.1083/jcb.200912056;
RA   Bompard G., Rabeharivelo G., Frank M., Cau J., Delsert C., Morin N.;
RT   "Subgroup II PAK-mediated phosphorylation regulates Ran activity
RT   during mitosis.";
RL   J. Cell Biol. 190:807-822(2010).
RN   [21]
RP   FUNCTION.
RX   PubMed=20631255; DOI=10.1091/mbc.E10-05-0429;
RA   Wallace S.W., Durgan J., Jin D., Hall A.;
RT   "Cdc42 regulates apical junction formation in human bronchial
RT   epithelial cells through PAK4 and Par6B.";
RL   Mol. Biol. Cell 21:2996-3006(2010).
RN   [22]
RP   REVIEW.
RX   PubMed=11950587; DOI=10.1016/S1357-2725(01)00158-3;
RA   Jaffer Z.M., Chernoff J.;
RT   "p21-activated kinases: three more join the Pak.";
RL   Int. J. Biochem. Cell Biol. 34:713-717(2002).
RN   [23]
RP   REVIEW ON FUNCTION.
RX   PubMed=20070256; DOI=10.1042/BJ20091173;
RA   Wells C.M., Jones G.E.;
RT   "The emerging importance of group II PAKs.";
RL   Biochem. J. 425:465-473(2010).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-474, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-181 AND SER-474, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-41; SER-181; THR-207 AND
RP   SER-474, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-181, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [29]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT LYS-78, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.O113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 300-591, AND PHOSPHORYLATION
RP   AT SER-474.
RA   Eswaran J., Debreczeni J.E., Bunkoczi G., Filippakopoulos P., Das S.,
RA   Fedorov O., Sundstrom M., Arrowsmith C., Edwards A., von Delft F.,
RA   Knapp S.;
RT   "Crystal structure of the human p21-activated kinase 4.";
RL   Submitted (JUL-2005) to the PDB data bank.
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.06 ANGSTROMS) OF 286-591 IN COMPLEX WITH
RP   FAM212A, FUNCTION, INTERACTION WITH FAM212A, AND ENZYME REGULATION.
RX   PubMed=26607847; DOI=10.1038/ncomms9681;
RA   Baskaran Y., Ang K.C., Anekal P.V., Chan W.L., Grimes J.M., Manser E.,
RA   Robinson R.C.;
RT   "An in cellulo-derived structure of PAK4 in complex with its inhibitor
RT   Inka1.";
RL   Nat. Commun. 6:8681-8681(2015).
RN   [32]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-135 AND THR-139.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine protein kinase that plays a role in a
CC       variety of different signaling pathways including cytoskeleton
CC       regulation, cell migration, growth, proliferation or cell
CC       survival. Activation by various effectors including growth factor
CC       receptors or active CDC42 and RAC1 results in a conformational
CC       change and a subsequent autophosphorylation on several serine
CC       and/or threonine residues. Phosphorylates and inactivates the
CC       protein phosphatase SSH1, leading to increased inhibitory
CC       phosphorylation of the actin binding/depolymerizing factor
CC       cofilin. Decreased cofilin activity may lead to stabilization of
CC       actin filaments. Phosphorylates LIMK1, a kinase that also inhibits
CC       the activity of cofilin. Phosphorylates integrin beta5/ITGB5 and
CC       thus regulates cell motility. Phosphorylates ARHGEF2 and activates
CC       the downstream target RHOA that plays a role in the regulation of
CC       assembly of focal adhesions and actin stress fibers. Stimulates
CC       cell survival by phosphorylating the BCL2 antagonist of cell death
CC       BAD. Alternatively, inhibits apoptosis by preventing caspase-8
CC       binding to death domain receptors in a kinase independent manner.
CC       Plays a role in cell-cycle progression by controlling levels of
CC       the cell-cycle regulatory protein CDKN1A and by phosphorylating
CC       RAN. {ECO:0000269|PubMed:11278822, ECO:0000269|PubMed:11313478,
CC       ECO:0000269|PubMed:14560027, ECO:0000269|PubMed:15660133,
CC       ECO:0000269|PubMed:20507994, ECO:0000269|PubMed:20631255,
CC       ECO:0000269|PubMed:20805321, ECO:0000269|PubMed:26607847}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Inhibited by FAM212A/INKA1; which inhibits the
CC       serine/threonine-protein kinase activity by binding PAK4 in a
CC       substrate-like manner (PubMed:26607847).
CC       {ECO:0000269|PubMed:26607847}.
CC   -!- SUBUNIT: Interacts with FGFR2 and GRB2 (By similarity). Interacts
CC       tightly with GTP-bound but not GDP-bound CDC42/p21 and weakly with
CC       RAC1 (PubMed:15827085). Interacts with FAM212A/INKA1
CC       (PubMed:26607847). {ECO:0000250|UniProtKB:Q8BTW9,
CC       ECO:0000269|PubMed:15827085, ECO:0000269|PubMed:26607847}.
CC   -!- INTERACTION:
CC       P60953:CDC42; NbExp=2; IntAct=EBI-713738, EBI-81752;
CC       P54274:TERF1; NbExp=2; IntAct=EBI-713738, EBI-710997;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12356872}.
CC       Note=Seems to shuttle between cytoplasmic compartments depending
CC       on the activating effector. For example, can be found on the cell
CC       periphery after activation of growth-factor or integrin-mediated
CC       signaling pathways. {ECO:0000269|PubMed:12356872}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=O96013-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O96013-2; Sequence=VSP_004892, VSP_004893;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=O96013-3; Sequence=VSP_017572;
CC       Name=4;
CC         IsoId=O96013-4; Sequence=VSP_017573;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Highest expression in prostate, testis and
CC       colon.
CC   -!- PTM: Autophosphorylated on serine residues when activated by
CC       CDC42/p21. {ECO:0000269|Ref.30}.
CC   -!- PTM: Phosphorylated on tyrosine residues upon stimulation of
CC       FGFR2. {ECO:0000250|UniProtKB:Q8BTW9}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. STE20 subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA86456.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAC11166.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ011855; CAA09820.1; -; mRNA.
DR   EMBL; AF005046; AAD01210.1; -; mRNA.
DR   EMBL; AB032968; BAA86456.1; ALT_INIT; mRNA.
DR   EMBL; AK074728; BAC11166.1; ALT_INIT; mRNA.
DR   EMBL; AK294586; BAG57777.1; -; mRNA.
DR   EMBL; AL834236; CAD38914.2; -; mRNA.
DR   EMBL; CH471126; EAW56861.1; -; Genomic_DNA.
DR   EMBL; BC002921; AAH02921.1; -; mRNA.
DR   EMBL; BC011368; AAH11368.1; -; mRNA.
DR   EMBL; BC025282; AAH25282.1; -; mRNA.
DR   EMBL; BC034511; AAH34511.1; -; mRNA.
DR   CCDS; CCDS12528.1; -. [O96013-1]
DR   CCDS; CCDS33019.1; -. [O96013-3]
DR   RefSeq; NP_001014831.1; NM_001014831.2. [O96013-1]
DR   RefSeq; NP_001014832.1; NM_001014832.1. [O96013-1]
DR   RefSeq; NP_001014834.1; NM_001014834.2. [O96013-3]
DR   RefSeq; NP_001014835.1; NM_001014835.1. [O96013-3]
DR   RefSeq; NP_005875.1; NM_005884.3. [O96013-1]
DR   RefSeq; XP_011524618.1; XM_011526316.1. [O96013-1]
DR   RefSeq; XP_011524619.1; XM_011526317.2. [O96013-1]
DR   RefSeq; XP_011524620.1; XM_011526318.2. [O96013-1]
DR   RefSeq; XP_011524621.1; XM_011526319.2. [O96013-1]
DR   RefSeq; XP_011524622.1; XM_011526320.1. [O96013-3]
DR   UniGene; Hs.20447; -.
DR   PDB; 2BVA; X-ray; 2.30 A; A/B=300-591.
DR   PDB; 2CDZ; X-ray; 2.30 A; A=291-591.
DR   PDB; 2J0I; X-ray; 1.60 A; A=291-591.
DR   PDB; 2OV2; X-ray; 2.10 A; I/J/K/L/M/N/O/P=10-44.
DR   PDB; 2Q0N; X-ray; 1.75 A; A=291-591.
DR   PDB; 2X4Z; X-ray; 2.10 A; A=297-591.
DR   PDB; 4APP; X-ray; 2.20 A; A=300-591.
DR   PDB; 4FIE; X-ray; 3.11 A; A/B=5-591.
DR   PDB; 4FIF; X-ray; 2.60 A; A/B=286-591, C/D=49-56.
DR   PDB; 4FIG; X-ray; 3.01 A; A/B=286-591.
DR   PDB; 4FIH; X-ray; 1.97 A; A=286-591.
DR   PDB; 4FII; X-ray; 2.00 A; A=286-591, B=49-56.
DR   PDB; 4FIJ; X-ray; 2.30 A; A=286-591.
DR   PDB; 4JDH; X-ray; 2.00 A; A=286-591.
DR   PDB; 4JDI; X-ray; 1.85 A; A=286-591.
DR   PDB; 4JDJ; X-ray; 2.30 A; A=286-591.
DR   PDB; 4JDK; X-ray; 2.40 A; A=286-591.
DR   PDB; 4L67; X-ray; 2.80 A; A=300-591, B=36-60.
DR   PDB; 4NJD; X-ray; 2.50 A; A=300-591.
DR   PDB; 4O0V; X-ray; 2.80 A; A=300-591.
DR   PDB; 4O0X; X-ray; 2.48 A; A=300-591.
DR   PDB; 4O0Y; X-ray; 2.20 A; A=300-591.
DR   PDB; 4XBR; X-ray; 2.94 A; A=278-591.
DR   PDB; 4XBU; X-ray; 2.06 A; A=286-591.
DR   PDB; 5BMS; X-ray; 2.90 A; A=300-591.
DR   PDB; 5I0B; X-ray; 3.09 A; A=300-591.
DR   PDBsum; 2BVA; -.
DR   PDBsum; 2CDZ; -.
DR   PDBsum; 2J0I; -.
DR   PDBsum; 2OV2; -.
DR   PDBsum; 2Q0N; -.
DR   PDBsum; 2X4Z; -.
DR   PDBsum; 4APP; -.
DR   PDBsum; 4FIE; -.
DR   PDBsum; 4FIF; -.
DR   PDBsum; 4FIG; -.
DR   PDBsum; 4FIH; -.
DR   PDBsum; 4FII; -.
DR   PDBsum; 4FIJ; -.
DR   PDBsum; 4JDH; -.
DR   PDBsum; 4JDI; -.
DR   PDBsum; 4JDJ; -.
DR   PDBsum; 4JDK; -.
DR   PDBsum; 4L67; -.
DR   PDBsum; 4NJD; -.
DR   PDBsum; 4O0V; -.
DR   PDBsum; 4O0X; -.
DR   PDBsum; 4O0Y; -.
DR   PDBsum; 4XBR; -.
DR   PDBsum; 4XBU; -.
DR   PDBsum; 5BMS; -.
DR   PDBsum; 5I0B; -.
DR   ProteinModelPortal; O96013; -.
DR   SMR; O96013; -.
DR   BioGrid; 115586; 49.
DR   DIP; DIP-39742N; -.
DR   IntAct; O96013; 21.
DR   MINT; MINT-1387795; -.
DR   STRING; 9606.ENSP00000351049; -.
DR   BindingDB; O96013; -.
DR   ChEMBL; CHEMBL4482; -.
DR   GuidetoPHARMACOLOGY; 2136; -.
DR   iPTMnet; O96013; -.
DR   PhosphoSitePlus; O96013; -.
DR   BioMuta; PAK4; -.
DR   EPD; O96013; -.
DR   MaxQB; O96013; -.
DR   PaxDb; O96013; -.
DR   PeptideAtlas; O96013; -.
DR   PRIDE; O96013; -.
DR   DNASU; 10298; -.
DR   Ensembl; ENST00000321944; ENSP00000326864; ENSG00000130669. [O96013-4]
DR   Ensembl; ENST00000358301; ENSP00000351049; ENSG00000130669. [O96013-1]
DR   Ensembl; ENST00000360442; ENSP00000353625; ENSG00000130669. [O96013-1]
DR   Ensembl; ENST00000593690; ENSP00000469413; ENSG00000130669. [O96013-1]
DR   Ensembl; ENST00000599386; ENSP00000471157; ENSG00000130669. [O96013-3]
DR   Ensembl; ENST00000599470; ENSP00000470284; ENSG00000130669. [O96013-3]
DR   GeneID; 10298; -.
DR   KEGG; hsa:10298; -.
DR   UCSC; uc002okj.2; human. [O96013-1]
DR   CTD; 10298; -.
DR   DisGeNET; 10298; -.
DR   GeneCards; PAK4; -.
DR   HGNC; HGNC:16059; PAK4.
DR   HPA; CAB025747; -.
DR   HPA; CAB044670; -.
DR   HPA; HPA070175; -.
DR   HPA; HPA072220; -.
DR   MIM; 605451; gene.
DR   neXtProt; NX_O96013; -.
DR   OpenTargets; ENSG00000130669; -.
DR   PharmGKB; PA32920; -.
DR   eggNOG; KOG0578; Eukaryota.
DR   eggNOG; ENOG410XP4K; LUCA.
DR   GeneTree; ENSGT00860000133680; -.
DR   HOVERGEN; HBG108518; -.
DR   InParanoid; O96013; -.
DR   KO; K05734; -.
DR   OMA; CQASHSS; -.
DR   OrthoDB; EOG091G0OT5; -.
DR   PhylomeDB; O96013; -.
DR   TreeFam; TF105352; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; R-HSA-428540; Activation of Rac.
DR   SignaLink; O96013; -.
DR   SIGNOR; O96013; -.
DR   ChiTaRS; PAK4; human.
DR   EvolutionaryTrace; O96013; -.
DR   GeneWiki; PAK4; -.
DR   GenomeRNAi; 10298; -.
DR   PRO; PR:O96013; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000130669; -.
DR   CleanEx; HS_PAK4; -.
DR   ExpressionAtlas; O96013; baseline and differential.
DR   Genevisible; O96013; HS.
DR   GO; GO:0005913; C:cell-cell adherens junction; IDA:BHF-UCL.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; TAS:ProtInc.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0098641; F:cadherin binding involved in cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0004672; F:protein kinase activity; NAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0006915; P:apoptotic process; TAS:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0016049; P:cell growth; TAS:UniProtKB.
DR   GO; GO:0016477; P:cell migration; TAS:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; TAS:UniProtKB.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IEA:Ensembl.
DR   GO; GO:0007010; P:cytoskeleton organization; TAS:UniProtKB.
DR   GO; GO:0060996; P:dendritic spine development; IEA:Ensembl.
DR   GO; GO:0006928; P:movement of cell or subcellular component; TAS:ProtInc.
DR   GO; GO:0007165; P:signal transduction; TAS:UniProtKB.
DR   CDD; cd01093; CRIB_PAK_like; 1.
DR   Gene3D; 3.90.810.10; -; 1.
DR   InterPro; IPR000095; CRIB_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR033923; PAK_BD.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   Pfam; PF00786; PBD; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00285; PBD; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50108; CRIB; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding;
KW   Cell cycle; Complete proteome; Cytoplasm; Kinase; Methylation;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1    591       Serine/threonine-protein kinase PAK 4.
FT                                /FTId=PRO_0000086474.
FT   DOMAIN       11     24       CRIB. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00057}.
FT   DOMAIN      321    572       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     327    335       ATP. {ECO:0000244|PDB:4XBR,
FT                                ECO:0000244|PDB:4XBU,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159,
FT                                ECO:0000269|PubMed:26607847}.
FT   NP_BIND     396    398       ATP analog. {ECO:0000244|PDB:4XBR,
FT                                ECO:0000244|PDB:4XBU,
FT                                ECO:0000269|PubMed:26607847}.
FT   NP_BIND     458    460       ATP analog. {ECO:0000244|PDB:4XBR,
FT                                ECO:0000244|PDB:4XBU,
FT                                ECO:0000269|PubMed:26607847}.
FT   REGION       25    320       Linker.
FT   REGION      298    323       GEF-interaction domain (GID).
FT   COMPBIAS    105    108       Poly-Pro.
FT   COMPBIAS    242    247       Poly-Ser.
FT   ACT_SITE    440    440       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     350    350       ATP. {ECO:0000244|PDB:4XBR,
FT                                ECO:0000244|PDB:4XBU,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159,
FT                                ECO:0000269|PubMed:26607847}.
FT   MOD_RES      41     41       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      78     78       N6-methyllysine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES     104    104       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     148    148       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     167    167       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     181    181       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     187    187       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     195    195       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     207    207       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     258    258       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     267    267       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     291    291       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     474    474       Phosphoserine; by autocatalysis.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|Ref.30}.
FT   VAR_SEQ      69    221       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:10574461,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_017572.
FT   VAR_SEQ     120    120       E -> K (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_004892.
FT   VAR_SEQ     121    285       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_004893.
FT   VAR_SEQ     132    221       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_017573.
FT   VARIANT     135    135       R -> Q (in dbSNP:rs56099436).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040970.
FT   VARIANT     139    139       A -> T (in dbSNP:rs35655056).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040971.
FT   MUTAGEN     445    445       S->N: Approximately 30-fold increased
FT                                autophosphorylation (constitutively
FT                                active mutant).
FT                                {ECO:0000269|PubMed:11313478}.
FT   MUTAGEN     474    474       S->E: Approximately 3-fold increased
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:11313478}.
FT   STRAND       15     26       {ECO:0000244|PDB:2OV2}.
FT   TURN         27     30       {ECO:0000244|PDB:2OV2}.
FT   STRAND       31     34       {ECO:0000244|PDB:2OV2}.
FT   HELIX        37     39       {ECO:0000244|PDB:2OV2}.
FT   TURN         40     42       {ECO:0000244|PDB:2OV2}.
FT   TURN         46     48       {ECO:0000244|PDB:4L67}.
FT   HELIX       301    311       {ECO:0000244|PDB:2J0I}.
FT   STRAND      312    315       {ECO:0000244|PDB:4O0Y}.
FT   HELIX       317    319       {ECO:0000244|PDB:2J0I}.
FT   STRAND      321    329       {ECO:0000244|PDB:2J0I}.
FT   STRAND      331    333       {ECO:0000244|PDB:4L67}.
FT   STRAND      334    340       {ECO:0000244|PDB:2J0I}.
FT   TURN        341    343       {ECO:0000244|PDB:2J0I}.
FT   STRAND      346    353       {ECO:0000244|PDB:2J0I}.
FT   HELIX       354    356       {ECO:0000244|PDB:2Q0N}.
FT   HELIX       360    362       {ECO:0000244|PDB:2J0I}.
FT   HELIX       363    369       {ECO:0000244|PDB:2J0I}.
FT   TURN        370    372       {ECO:0000244|PDB:2J0I}.
FT   STRAND      381    387       {ECO:0000244|PDB:2J0I}.
FT   STRAND      390    395       {ECO:0000244|PDB:2J0I}.
FT   HELIX       403    409       {ECO:0000244|PDB:2J0I}.
FT   HELIX       414    433       {ECO:0000244|PDB:2J0I}.
FT   HELIX       443    445       {ECO:0000244|PDB:2J0I}.
FT   STRAND      446    448       {ECO:0000244|PDB:2J0I}.
FT   STRAND      454    456       {ECO:0000244|PDB:2J0I}.
FT   HELIX       459    461       {ECO:0000244|PDB:4FII}.
FT   STRAND      467    469       {ECO:0000244|PDB:2J0I}.
FT   STRAND      475    477       {ECO:0000244|PDB:2Q0N}.
FT   HELIX       479    481       {ECO:0000244|PDB:2J0I}.
FT   HELIX       484    487       {ECO:0000244|PDB:2J0I}.
FT   HELIX       495    510       {ECO:0000244|PDB:2J0I}.
FT   TURN        514    517       {ECO:0000244|PDB:2J0I}.
FT   HELIX       520    529       {ECO:0000244|PDB:2J0I}.
FT   HELIX       538    540       {ECO:0000244|PDB:2J0I}.
FT   HELIX       543    552       {ECO:0000244|PDB:2J0I}.
FT   TURN        557    559       {ECO:0000244|PDB:2J0I}.
FT   HELIX       563    566       {ECO:0000244|PDB:2J0I}.
FT   HELIX       570    574       {ECO:0000244|PDB:2J0I}.
FT   HELIX       578    581       {ECO:0000244|PDB:2J0I}.
FT   HELIX       582    584       {ECO:0000244|PDB:2J0I}.
FT   TURN        586    588       {ECO:0000244|PDB:2J0I}.
SQ   SEQUENCE   591 AA;  64072 MW;  04C2A5C0B06427D5 CRC64;
     MFGKRKKRVE ISAPSNFEHR VHTGFDQHEQ KFTGLPRQWQ SLIEESARRP KPLVDPACIT
     SIQPGAPKTI VRGSKGAKDG ALTLLLDEFE NMSVTRSNSL RRDSPPPPAR ARQENGMPEE
     PATTARGGPG KAGSRGRFAG HSEAGGGSGD RRRAGPEKRP KSSREGSGGP QESSRDKRPL
     SGPDVGTPQP AGLASGAKLA AGRPFNTYPR ADTDHPSRGA QGEPHDVAPN GPSAGGLAIP
     QSSSSSSRPP TRARGAPSPG VLGPHASEPQ LAPPACTPAA PAVPGPPGPR SPQREPQRVS
     HEQFRAALQL VVDPGDPRSY LDNFIKIGEG STGIVCIATV RSSGKLVAVK KMDLRKQQRR
     ELLFNEVVIM RDYQHENVVE MYNSYLVGDE LWVVMEFLEG GALTDIVTHT RMNEEQIAAV
     CLAVLQALSV LHAQGVIHRD IKSDSILLTH DGRVKLSDFG FCAQVSKEVP RRKSLVGTPY
     WMAPELISRL PYGPEVDIWS LGIMVIEMVD GEPPYFNEPP LKAMKMIRDN LPPRLKNLHK
     VSPSLKGFLD RLLVRDPAQR ATAAELLKHP FLAKAGPPAS IVPLMRQNRT R
//
